🔗 Share this article

While the United States proceeds with sweeping adjustments to its vaccination recommendations, an unexpected name appears unexpectedly: Høeg, an American of Danish descent physician and public health researcher who rose to prominence by expressing skepticism about Covid shots throughout the global health crisis and has focused upon alleged fatalities following COVID-19 vaccination in her brief time at the FDA.

Proposed Changes to Childhood Vaccine Program

Public health authorities had intended to reveal sweeping revisions to the pediatric vaccine schedule earlier this month, bringing the US with Denmark’s immunization schedule, according to reports – a significant shift that would place the US out of alignment with a large portion of the global community with insufficient data for benefit. This reveal has been pushed back until the coming year.

In place of the top vaccines chief, Høeg is scheduled to present at the meeting. She was just designated acting director of the FDA’s drug evaluation center, the fifth appointee to lead the office this year.

Consolidating Power at the FDA

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad solidify control at the agency – and it signals a greater focus upon dismantling already-approved immunizations at the FDA.

The new acting director has repeatedly called for ending specific childhood immunization guidelines in the US so as to align more similar to the Danish model, a society with nationalized medicine and a population approximately the size of the state of Wisconsin.

So far statements, she has continued to focus on vaccination policy – usually the domain of Dr. Prasad, head of the FDA’s vaccine center – instead of medication approval.

Concerns Over Background

The appointee has no obvious background in medication creation, regulation or leadership, which has been customary for past directors of the biologics center. She has been employed at the FDA as a key advisor to the FDA chief and CBER since earlier this year.

“She doesn’t seem to have the requisite experience” for overseeing the CDER, stated Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She has no expertise in running a major agency. She has no expertise in pharmaceutical oversight.”

Past commissioners of the center would “be deeply familiar with regulatory frameworks and the science of pharmaceutical innovation”, said Dr. Janet Woodcock. “Objectively, she lacks the type of experience that previous people who ran CBER have had.”

The drug center has an vast portfolio at the FDA, Woodcock stated.

“Everybody just focuses on the new drug program, but the generic program approves a multitude of generic medications. There is also a biologic copycat branch, OTC medication office and other areas, and each of these must be looked after,” Dr. Woodcock said. “The area you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a major management component to the job, which manages in excess of 5,000 personnel. “It’s a enormous management job, if you do it right,” the former official added.

Agency Reaction and Contentious Initiatives

In response to questions about Dr. Høeg's credentials and whether this appointment indicates increased cooperation among regulatory chiefs on immunizations, a press secretary said that the “questions rely on incorrect presumptions”.

“This background aligns with the functions of her role,” the official said, pointing to the months Høeg spent guiding the agency head on “medication safety and oversight research, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg takes over the commissioner’s recently launched priority voucher program, a disputed expedited drug-approval program that apparently concerned her former heads. “How are these therapies being selected for this expedited pathway? Who is making the calls?” Howard questioned. “There is a lot of lack of transparency going on at the regulatory body right now.”

In general, he said, “the FDA looks to be trending towards more relaxed oversight of most medications, with the exception of shots.”

Documented Past Work on Vaccines

With immunizations, Dr. Høeg has a more documented, if problematic, history, critics said. She authored a research paper using unconfirmed crowd-sourced reports to determine the frequency of heart inflammation after COVID-19 immunization. She counseled the state of Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccines are riskier than they are.

Part of her “wish list” for the current administration included altering rules for recently developed shots and halting “unnecessary” vaccines, she remarked post-election on a podcast. At the agency, Dr. Høeg has allegedly suggested barring teenage boys from getting COVID-19 vaccinations.

“She is an thorough dogmatist who commences with her preconceived notions and works backwards to fit the data in a highly deceptive, untruthful fashion,” Dr. Howard argued.

Consolidating Power and a “Push for Payback”

Dr. Høeg joined other contrarians, {like|